(1 - 6 von 13
)
Regulatory roundup - DDNewswww.ddn-news.com › ...
www.drugdiscoverynews.com
percent of bone marrow transplant patients and is a substantial contributor to transplant-related morbidity and mortality,” said Alon Moran, CEO of Enlivex.
Licensing Deals - PR Newswire Association LLC.
www.cypriotbiotech.com
Enlivex CEO, Alon Moran, commented, "The results from our Phase I/II clinical trials showed safety as well as an impressive indication of efficacy using our ...
sortiert nach Relevanz / Datum